OSE IMMUNO (OSE.PA)
FR0012127173 - Common Stock
OSE gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 76 industry peers in the Biotechnology industry. OSE has a great financial health rating, but its profitability evaluates not so good. OSE is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
OSE had negative earnings in the past year.
OSE had a positive operating cash flow in the past year.
OSE had negative earnings in each of the past 5 years.
In the past 5 years OSE reported 4 times negative operating cash flow.
1.2 Ratios
OSE has a Return On Assets of -16.32%. This is in the better half of the industry: OSE outperforms 63.38% of its industry peers.
With a decent Return On Equity value of -28.24%, OSE is doing good in the industry, outperforming 61.97% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.32% | ||
| ROE | -28.24% | ||
| ROIC | N/A |
ROA(3y)-21.31%
ROA(5y)-17.25%
ROE(3y)-63.23%
ROE(5y)-44.92%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for OSE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OSE does not have a ROIC to compare to the WACC, probably because it is not profitable.
OSE has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, OSE has more shares outstanding
The debt/assets ratio for OSE is higher compared to a year ago.
2.2 Solvency
OSE has an Altman-Z score of 2.22. This is not the best score and indicates that OSE is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.22, OSE is in the better half of the industry, outperforming 67.61% of the companies in the same industry.
OSE has a debt to FCF ratio of 0.76. This is a very positive value and a sign of high solvency as it would only need 0.76 years to pay back of all of its debts.
OSE's Debt to FCF ratio of 0.76 is amongst the best of the industry. OSE outperforms 95.77% of its industry peers.
A Debt/Equity ratio of 0.49 indicates that OSE is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.49, OSE is in line with its industry, outperforming 50.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 0.76 | ||
| Altman-Z | 2.22 |
ROIC/WACCN/A
WACC7.65%
2.3 Liquidity
A Current Ratio of 4.93 indicates that OSE has no problem at all paying its short term obligations.
OSE has a better Current ratio (4.93) than 78.87% of its industry peers.
A Quick Ratio of 4.93 indicates that OSE has no problem at all paying its short term obligations.
OSE has a better Quick ratio (4.93) than 81.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.93 | ||
| Quick Ratio | 4.93 |
3. Growth
3.1 Past
The earnings per share for OSE have decreased strongly by -22.67% in the last year.
Looking at the last year, OSE shows a very negative growth in Revenue. The Revenue has decreased by -87.83% in the last year.
OSE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -38.07% yearly.
EPS 1Y (TTM)-22.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%456.48%
Revenue 1Y (TTM)-87.83%
Revenue growth 3Y-40.23%
Revenue growth 5Y-38.07%
Sales Q2Q%5980.49%
3.2 Future
Based on estimates for the next years, OSE will show a very strong growth in Earnings Per Share. The EPS will grow by 54.48% on average per year.
The Revenue is expected to grow by 82.24% on average over the next years. This is a very strong growth
EPS Next Y288.54%
EPS Next 2Y92.32%
EPS Next 3Y54.48%
EPS Next 5YN/A
Revenue Next Year320.57%
Revenue Next 2Y85.62%
Revenue Next 3Y82.24%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for OSE. In the last year negative earnings were reported.
OSE is valuated cheaply with a Price/Forward Earnings ratio of 4.99.
Compared to the rest of the industry, the Price/Forward Earnings ratio of OSE indicates a rather cheap valuation: OSE is cheaper than 94.37% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.63, OSE is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.99 |
4.2 Price Multiples
100.00% of the companies in the same industry are more expensive than OSE, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.87 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
OSE's earnings are expected to grow with 54.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y92.32%
EPS Next 3Y54.48%
5. Dividend
5.1 Amount
No dividends for OSE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSE IMMUNO
EPA:OSE (10/21/2024, 5:27:20 PM)
10.34
+0.51 (+5.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap224.93M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.99 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.32% | ||
| ROE | -28.24% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.93 | ||
| Quick Ratio | 4.93 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-22.67%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y288.54%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-87.83%
Revenue growth 3Y-40.23%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y